Efficacy and Safety of Albumin-bound Paclitaxel Combined with Nedaplatin in Concurrent Chemoradiotherapy for Cervical Cancer
Objective To investigate the efficacy and safety of albumin-bound paclitaxel combined with nedaplatin in concurrent chemoradiotherapy for patients with cervical cancer,aiming to provide clinical treatment options and improve patients'quality of life.Methods 80 cervical cancer patients who visited Xinxiang First People's Hospital from August 2021 to August 2023 were selected and randomly divided into a study group and a control group with 40 patients in each group using a random number table method.The control group received radiotherapy alone,while the study group received concurrent chemotherapy with albumin-bound paclitaxel and nedaplatin on the basis of the control group's treatment.The disease control rate,quality of life scores before treatment and after 6 weeks of treatment,median progression-free survival(PFS),2-year survival rate,and adverse reactions were compared between the 2 groups.Results The disease control rate in the study group[95.00%(38/40)]was significantly higher than that in the control group[80.00%(32/40)](P＜0.05).Compared with the control group,the study group had higher scores for social function,somatic function,psychological function,material function,and overall quality of life after 6 weeks of treatment(P＜0.05);after 2 years of follow-up,the PFS and 2-year survival rate in the study group were significantly higher than those in the control group(P＜0.05).There were no statistically significant differences in adverse reactions such as myelosuppression gradeⅢ—Ⅳ,gastrointestinal reactions,liver and kidney function impairment,alopecia,and peripheral neuropathy between the 2 groups during treatment(P＞0.05).However,the incidence of myelosuppression grade Ⅰ—Ⅱ in the study group was lower than that in the control group(P＜0.05).Conclusion Concurrent chemoradiotherapy with albumin-bound paclitaxel and nedaplatin can improve the disease control rate and enhance quality of life for patients with intermediate and advanced cervical cancer.It can effectively reduce the incidence of myelosuppression during treatment,demonstrating relatively good safety profile.
cervical canceralbumin-bound paclitaxelnedaplatinadverse reactionquality of life
NETL
NSTL
万方数据
